Clinical Trial Update: A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) [Phase 1]

View source ↗

Summary

Phase 1 study of AUR104 in select relapsed/refractory lymphoid malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies

Drugs mentioned

• AUR104 (AUR104)

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Status: TERMINATED